ARTS-023

N/A

Report date: 2025/10/20 16:22:10
NME

Base Information

Drug NameARTS-023
Drug Alias NameARTS-023AVZO-023ARTS023
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAvenzo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvenzo Therapeutics IncAnrui Biomedical Technology (Guangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursHR-positive breast cancer +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A